- Home
- OPP vs ADCT Comparison
OPP vs ADCT Comparison
Compare OPP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- ADCT
- Stock Information
- Founded
- OPP 2010
- ADCT 2011
- Country
- OPP United States
- ADCT Switzerland
- Employees
- OPP N/A
- ADCT N/A
- Industry
- OPP Finance/Investors Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- OPP Finance
- ADCT Health Care
- Exchange
- OPP Nasdaq
- ADCT Nasdaq
- Market Cap
- OPP 200.8M
- ADCT 224.3M
- IPO Year
- OPP N/A
- ADCT 2020
- Fundamental
- Price
- OPP $8.34
- ADCT $2.05
- Analyst Decision
- OPP
- ADCT Strong Buy
- Analyst Count
- OPP 0
- ADCT 5
- Target Price
- OPP N/A
- ADCT $8.00
- AVG Volume (30 Days)
- OPP 108.0K
- ADCT 1.6M
- Earning Date
- OPP 01-01-0001
- ADCT 11-07-2024
- Dividend Yield
- OPP 14.41%
- ADCT N/A
- EPS Growth
- OPP N/A
- ADCT N/A
- EPS
- OPP N/A
- ADCT N/A
- Revenue
- OPP N/A
- ADCT $70,717,000.00
- Revenue This Year
- OPP N/A
- ADCT $6.58
- Revenue Next Year
- OPP N/A
- ADCT $11.78
- P/E Ratio
- OPP N/A
- ADCT N/A
- Revenue Growth
- OPP N/A
- ADCT N/A
- 52 Week Low
- OPP $7.26
- ADCT $1.18
- 52 Week High
- OPP $8.83
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- OPP 36.36
- ADCT 45.58
- Support Level
- OPP $8.43
- ADCT $1.80
- Resistance Level
- OPP $8.75
- ADCT $3.49
- Average True Range (ATR)
- OPP 0.09
- ADCT 0.40
- MACD
- OPP -0.01
- ADCT -0.02
- Stochastic Oscillator
- OPP 9.84
- ADCT 21.01
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.